Company Presentation – January 2017

1

This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federalsecurities laws. For example, we are using forward-looking statements when we discuss the expected timing of obtaining regulatory approval for our variouspatient trials and clinical data readout, proposed trials that may occur in the future, the timing and implementation of our collaborations with various partnersand the execution of definitive agreements relating to such collaborations and the potential benefits and impact our products could have on improving patienthealth care. These forward-looking statements and their implications are based on the current expectations of our management only, and are subject to anumber of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The followingfactors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and marketrequirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved byregulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may beunable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop withour process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinicalsettings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harmrecipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure onpricing resulting from competition, which could cause our actual results or performance to differ materially from those contemplated in such forward-lookingstatements. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflectevents or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertaintiesaffecting us, reference is made to our reports filed from time to time with the Securities and Exchange Commission

Forward looking Statement

2

• Cell therapy company entering late-stage trials in 3 indications

• Multifactorial cell therapy releasing a range of therapeutic proteins in responseto signals from the patient's body

• No tissue matching or immunosuppression is required to administer our placenta-derived cell products

• First in class 3D cell culturing technology allowing for efficient, controlledproduction of different cell products in commercial quantities

Pluristem corporate overview

• Regulatory approval for clinical trials in US, EU, Japan, South Korea, Australia and Israel

3

• Cell therapy (Bio-therapy) company using off-the-shelf, placental-expanded cells to achieve

local and systemic therapeutic effects

Pluristem corporate overview

4

Japan - Accelerated Pathway for Regenerative Medicine

Europe - Adaptive Pathways pilot project

Change in the Regulatory Environment

European initiative intended to grant earlier access to drugs meant to treat debilitatingand life-threatening diseases with unmet medical needEarlier entry to a multi-billion dollar market

New Japanese regulations to accelerate development of drugs in the field ofregenerative therapy

Conditional approval for marketing and reimbursement upon proof of safety and asignal of effectiveness

Pluristem’s PLX-PAD program was selected for both pathways5

USA- 21st Century Cures Act

Change in the Regulatory Environment

Expedited approval pathway for regenerative advanced therapies Allows shorter time frames for marketing approval Creating medical and economic benefits for the healthcare system and reduce costs

of development facilitate early patient access to therapies with proven efficacy

The 21ST century cure act is an extremely significant healthcarelegislation that may have a direct and beneficial impact onPluristem’s clinical development programs and progress towardsapproval for our cell therapies

6

• Public company, Traded on:

• Market Cap: ~ $125 million

• Cash and marketable securities: $29 million (as of September 30, 2016)

Term sheet signed with Innovative Medical/ZSVC for $30 million investment

Binding term sheet with Sosei who will invest $11 million in a JV in Japan

During 2016 we received $12 million in grants approved

(Horizon 2020- ~$8m, Israeli Government ~$3m, Bird foundation ~$1m)

• No debt

• 170 employees (18 PhD, 5 MD)

• IP Ownership: over 85 granted patents and ~120 pending applications

PSTI PSTI/ PLTR

Financial Glance

7

Indication

Critical Limb Ischemia (CLI)*

Hip Fracture**

Acute Radiation Syndrome (ARS)

Location

U.S.Europe

Japan

U.S./ Europe

U.S.

Pivotal pre-marketing trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX- PAD

PLX- R18

Conditional Approval Pathway

* One Multinational trial- U.S- phase 3, Europe- via adaptive pathway allowing early marketing approval** Pending FDA/EMA approval

Pivotal study via FDA Animal Rule

8

PLX-PAD

Critical Limb Ischemia (CLI)Hip Fracture

9

• 5-6 million people in U.S and Europe suffer from CLI

• Estimated cost for treating CLI is $25 billion per year

• Obstruction of arteries in the leg

• High mortality

• High amputation rates

• Poor treatment options

CLI & Market Size

Source: Lifecells LLC

Source: Sage group

10

• Amputation Free Survival at 6 months:

• US (total n=12) - 100%

• Germany (total n=15) - 93%

• Comparison to published data on no-option CLI:‒ TASC II: 20% death and 40% major amputations in 6m

‒ TAMARIS (n=259 control pts.): 76% AFS in 6m (196/259)

‒ Meta-analyses (Benoit 2011, Weems 2015): 67%-77% AFS at 6m

‒ The majority of events usually occur in the first 6m

Early Clinical Studies Support Design of Pivotal Phase 3 Trial

Pre-Treatment

8 Weeks After Treatment

11

• Amputation Free Survival at 12 months:

• US (total n=12) - 100%

• Germany (total n=15) - 73%

• Comparison to published data on

no-option CLI:‒ TASC II - (all CLI): 45% AFS, 30% MA &

25% death at 1y‒ Reinecke 2015 - (all CLI): 68% AFS at 1y

R4+R5

Early Clinical Studies Support Design of Pivotal Phase 3 Trial

12

Targeting marketing approval in both U.S. and Europe using data from asingle pivotal Phase III trial in 250 patients

Awarded $8 Million Grant from Europe’s Horizon 2020 Program

75-patient study design was agreed upon with Japanese PMDA. This singlestudy may lead to early conditional marketing approval and earlyreimbursement

Binding term sheet with Sosei for the establishment of JV for theclinical development and commercialization of PLX-PAD for CLI in Japan

CLI Clinical Development Towards Marketing

13

• Primary endpoint is time to event (amputation or death)

Allows for collection of more data during the trial thereby significantly

reducing the number of patients needed

• Other methods of efficacy include: AFS, Quality of life, TcPO2, Pain Score

• Dosing regimen: two doses of 300 million cells, two months apart

• No HLA matching or immunosuppression required

Study Design for U.S. Pivotal Phase 3 Trial (N=250)

14

Phase III study cleared by the FDA

PLX-PAD program in CLI selected for EU EMAadaptive pathways pilot project

PLX-PAD program in CLI selected for JapanesePMDA conditional approval pathway forRegenerative Medicine

Binding term sheet with Sosei for the establishmentof JV for the clinical development andcommercialization of CLI in Japan

Phase III study cleared by UK Regulatory Agency(MHRA)

Phase III study cleared by German PEI (Paul EhrlichInstitute)

CLI Study Wins $8 Million Grant from Europe’sHorizon 2020 Program

U.S /Europe phase III study initiation- Q1/2017

Japan pivotal study initiation – H2 2017

Closing on JV deal with Sosei- Q1/2017

Data from IC phase multinational phase II study,N=172 - early 2018

Interim result from Europe phase III (viaadaptive pathway)- H2 2018/H1 2019

Recent Events Expected MilestonesCritical Limb Ischemia (CLI)

15

Indication

Critical Limb Ischemia (CLI)*

Hip Fracture**

Acute Radiation Syndrome (ARS)

Location

U.S.Europe

Japan

U.S./ Europe

U.S.

Pivotal pre-marketing trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX- PAD

PLX- R18

Conditional Approval Pathway

* One Multinational trial- U.S- phase 3, Europe- via adaptive pathway allowing early marketing approval** Pending FDA/EMA approval

Pivotal study via FDA Animal Rule

16

Muscle Injury following Total Hip Replacement (N=20)

Improvement of 500%

P=0.0067

Change at week 26 in Mean (±SE) Gluteus Medius

MVIC from Day 0 (mITT)

MVIC = Maximum Voluntary Isometric Construction

Orthopedic – Strong Clinical Data

17

Muscle Injury following Total Hip Replacement (N=20)

Change in Volume from Day 0

Orthopedic – Strong Clinical Data

Improvement of 300%

P=0.004

18

Muscle Injury following Total Hip Replacement (N=20)

Injured (operated) Contralateral(non–operated)

Orthopedic – Strong Clinical Data

Improvement of 4000%

P=0.012

19

Hip Fracture PLX-PAD program in hip fracture might be eligible for Breakthrough

Therapy designation and benefit from the 21st Century Cures Act aswell as the EMA’s Adaptive Pathways pilot project

Pluristem intends to conduct a Phase III trial assessing PLX-PAD cellsin recovery following surgery for femoral neck fracture

Femoral neck fracture is the most common form of hip fracture Annual treatment costs in the U.S. are estimated to be between $10

to $15 billion, and are expected to rise due to the aging population,with mortality rates of up to 36%*

Previous studies have shown that PLX-PAD stimulates repair ofdamaged muscle and can play a critical role in improving theoutcomes of the growing number of surgeries for femoral neckfracture

*

20

PLX-R18

Acute Radiation Syndrome (ARS)Hematopoietic Cell Transplantation Failure

Support for Hematopoietic Cell Transplantation

21

Indication

Critical Limb Ischemia (CLI)*

Hip Fracture**

Acute Radiation Syndrome (ARS)

Location

U.S.Europe

Japan

U.S./ Europe

U.S.

Pivotal pre-marketing trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX- PAD

PLX- R18

Conditional Approval Pathway

* One Multinational trial- U.S- phase 3, Europe- via adaptive pathway allowing early marketing approval** Pending FDA/EMA approval

Pivotal study via FDA Animal Rule

22

Collaboration for ARS with U.S. Government U.S. National Institutes of Health to Support Development of Pluristem's PLX-R18

Collaboration with Fukushima Medical University and Science Center to developPLX-R18 cells for the treatment of other component of ARS (GI, Lung and Skin),

and for morbidities following radiotherapy in cancer patients23

PLX-R18 Treated Mice Exhibit IncreasedWeight and Survival Rate

* p value < 0.05** p value < 0.01*** p value < 0.001

68 %

30/31

p va

lue

< 0.

0001

9/31irradiated + vehicle

irradiated + PLX-R18

******

***

**

irradiated + vehicle

irradiated + PLX-R18

Survival Weight

24

Wang and Wagers. 2011. Nat Rev MCB 12:643

Maintenance ofHematopoietic niche

Mobilization of differentiated cells into peripheral blood and

chemoattractants

Renewal, Differentiation and mobilization of Hematopoietic cells

EpoG-CSF (CSF3)GM-CSF (CSF2) SCF (KITLG)IL-2GRO-β (CXCL2)

MCP-1 (CCL2)MCP-3 (CCL7)SDF1α(CXCL12)SCF (KITLG)IL-8GCP2/CXCL6GRO-β (CXCL2)

SCF (KITLG)GRO-β (CXCL2)PGE-2SDF1α(CXCL12)ANGPT1VEGF

IL-3LIFMIFIL-6VEGF

Mechanism of Action

25

FDA approval of Phase I study for the treatment of insufficient hematopoietic recovery following hematopoietic cell transplant− N=30, U.S. clinical sites− open-label trial allows for interim data analysis

Collaboration with New York Blood Center to evaluate PLX-R18 as an adjuvant therapy to umbilical cord blood transplantation− Grant of $900,000 from Israel-U.S. Binational Industrial Research and

Development Foundation (BIRD)− 3rd potential hematologic indication for PLX-R18

PLX-R18 Additional Hematologic Indications

26

FDA clearance of phase I trial for the treatmentof insufficient hematopoietic recoveryfollowing Bone Marrow Transplant

NIH advancing to second cohort of doseselection study in ARS- FDA animal rulepathway

Collaboration with New York Blood Center inevaluating PLX-R18 as an adjuvant therapy toumbilical cord blood transplantation

Grant of $900,000 from Israel - U.S. BinationalIndustrial Research and DevelopmentFoundation (BIRD)

MOU for Collaboration with FukushimaMedical University to Study PLX-R18 in ARS

Data readout dose selection studies ARS-H1/2017

Contract with U.S. government for ARS –H2/2017

Initiation of pivotal study ARS NHP-H2/2017

Data readout phase I open label HCT-H2/2017

Preclinical data Fukushima- H1/2017

Preclinical data NYBC- H1/2017

Recent Events Expected MilestonesPLX-R18

27

Indication

Intermittent Claudication (IC)

Support for Hematopoietic Cell Transplantation

Hematopoietic Cell Transplantation failure

Additional Clinical Trials

Company Pipeline

Pre-Clinical Phase 2Phase 1 Phase 3 MarketProduct

PLX-PAD

PLX-R18

PLX- R18

Cleared for U.S. FDA phase 1 study

28

• Rich & Diverse• Highly potent

• pro-angiogenic• immunoregulatory

• Young donors• Unlimited source• Easy to collect• Ethically accepted• Over 20,000 Doses of 300

million cells per placenta

The NIH Placenta ProjectLaunched by the U.S. NationalInstitutes of Health (NIH) toFurther explore the role of theplacenta in health and disease.

Placenta derived cells

29

Culture conditions

PLX-R18Hematological

PLX-PADAngiogenesis

Culture conditions

PLX-CNSNeuronal

PLX-IMMUNEImmunological

Each PLX Product Secretes a Different Range of Proteins to Address Different Varieties of Indications

Culture conditions

Culture conditions

Human placenta- a platform for cell products

Stimulates regeneration of damaged bone marrow to produce blood cells (white, red and platelets)

Reduces inflammation Stimulates growth of collateral blood

vessels Stimulates repair of damaged muscle30

3D Manufacturing, in-house cell production150,000 doses annually

31

CMC & Manufacturing Facility for PLX-PAD approved by FDA,

German, EU, South Korean, Japanese &

Israeli Regulatory Agencies for 3D

culturing for Phase II, III trials and marketing

32

1. Out-licensing commercialization deals with partners.

2. Direct sales of our ‘R18’ product for Acute Radiation Syndrome

3. Direct sales of indications with small patients population, & high price

Commercialization Strategy

33

CollaborationsPartner Indication Deal structure

IC, CLISouth Korea only

Joint Venture following marketing authorization bythe South Korean authorities

Acute Radiation Syndrome

U.S. National Institutes of Health (NIH) to SupportDevelopment of PLX-R18

Acute Radiation Syndrome

Pluristem will contribute cells and scientificknowledge, FMU will conduct the studies andprovide the required resources.

Acute Radiation Syndrome

Conducting trials to test PLX-R18 cells in thetreatment of ARS and understanding of MOA

CLI, Immunology,Cardiovascular,

Orthopedic

Research to test the unique immunology of theplacenta and cells MOA

Umbilical Cord Blood

Transplantation

Evaluating PLX-R18 as an Adjuvant Therapy toUmbilical Cord Blood Transplantation

Pluristem keeps IP and manufacturing

rights in all collaborations

34

Initiate advanced pivotal (pre-marketing) clinical trials:• Critical Limb Ischemia (CLI) – U.S., EU, Japan

• Hip fracture – U.S., EU

• ARS

Clinical data readout

• Intermittent Claudication (IC)

• ARS- U.S. NIH dose selection trial

• Incomplete engraftment of hematopoietic cell transplantation – open label

Business development

• Japan- close the Sosei deal and form a JV

• U.S. – negotiating contract with government for ARS

• China- licensing/JV with Chinese partner

Upcoming Milestones – 12 Months

35

Advanced Pipeline • Cleared to begin a multinational Phase 3 trial in CLI in U.S., U.K. and Germany

• Potential for early conditional approval in Europe• Preparing multinational Phase 3 trial in recovery after hip fracture• U.S. NIH conducting dose-selection trial in ARS

Commercial-grade Manufacturing

• In-house CMC manufacturing with certified batch-to-batch consistency

• Production technology for PLX-PAD approved by U.S. and EU regulators through commercialization

• Patented 3D culturing technology is easily scalable and extremely efficient/cost effective

Unique products that are

convenient to use

• Two distinct cell products in clinical trials – each customized for different indications

• No matching required prior to administration – off-the-shelf with low immunogenicity confirmed

• IM administration designed for use in most clinical settings

Investment Proposition

36

Zami AbermanChairman & CEO

Efrat Livne-Hadass VP Human Resources

Racheli Ofir, Ph.D.VP Research & Intellectual Property

Sagi MoranVP Operations

Erez Egozi VP Finance

Karine Kleinhaus, M.D., MPHDivisional VP, North America

Esther Lukasiewicz Hagai, M.D., Ph.D. VP Clinical & Medical Affairs

Lior RavivVP Development

Hillit Mannor Shachar, M.D., M.B.A.VP Business Development

Yaky YanayPresident & COO

Orly AmiranVP Quality Assurance

Management team

37

Thank you!

38